Clinical Trials Logo

Pulmonary Fibrosis clinical trials

View clinical trials related to Pulmonary Fibrosis.

Filter by:

NCT ID: NCT05130970 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

CSL312 Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis

Start date: January 27, 2022
Phase: Phase 2
Study type: Interventional

This is a prospective, phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of CSL312 in subjects with idiopathic pulmonary fibrosis (IPF).

NCT ID: NCT05113654 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

Sleep Disorders in Idiopathic Pulmonary Fibrosis

Start date: April 26, 2016
Phase:
Study type: Observational

This diagnostic observational study was conducted to (1) investigate the prevalence of sleep-related breathing disorders and other sleep disorders in idiopathic pulmonary fibrosis in comparison to COPD, (2) identify characteristics of symptomatic and prognostic significance in idiopathic pulmonary fibrosis with/without sleep disorders, and (3) evaluate different tools for their ability to assess the risk of co-existing sleep disorders in idiopathic pulmonary fibrosis.

NCT ID: NCT05095363 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

Palliative Care Planner (PCplanner)

Start date: March 16, 2022
Phase: N/A
Study type: Interventional

The purpose of this research study is to determine the feasibility, acceptability, and evidence for clinical impact of a mobile app-based program called Palliative Care Planner (PCplanner) in addressing needs and promoting advance care planning discussions among patients with idiopathic pulmonary fibrosis and their clinicians.

NCT ID: NCT05022784 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

Adherence to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients

Start date: August 23, 2021
Phase:
Study type: Observational

This is a non-interventional cohort study using existing administrative data from the U.S. Medicare program. This study has two objectives: - Identification of adherence trajectories of nintedanib among Idiopathic Pulmonary Fibrosis (IPF) patients. - Understanding characteristics of patients within each nintedanib adherence trajectory among IPF patients.

NCT ID: NCT05022771 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of PMG1015

Start date: October 14, 2021
Phase: Phase 1
Study type: Interventional

This is a Phase 1A, first in human, randomized, double-blinded, placebo-controlled, dose escalation study of PMG1015 in healthy adult volunteers. PMG1015 is a monoclonal antibody, being developed as a novel therapeutic treatment for patients with Idiopathic Pulmonary fibrosis (IPF). This study aims to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PMG1015 after Single ascending doses (SAD).

NCT ID: NCT04987606 Completed - COVID-19 Pneumonia Clinical Trials

Post COVID-19 Interstitial Lung Disease: A Study of Genetic and Environmental Interactions

POSTCODE
Start date: July 1, 2021
Phase:
Study type: Observational

This study aims to understand why some people who have had COVID-19 develop scarring of the lungs and why some people recover more quickly than others.

NCT ID: NCT04986540 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

A Trial of SHR - 1906 in Healthy Subjects

Start date: August 10, 2021
Phase: Phase 1
Study type: Interventional

This study is a phase 1 single dose escalation study of SHR-1906 in healthy subjects. The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of SHR-1906 in healthy subjects.

NCT ID: NCT04979884 Completed - Pulmonary Fibrosis Clinical Trials

Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Hospital

Start date: January 3, 2022
Phase: Phase 3
Study type: Interventional

The study to evaluate the effect of cyclosporine ( IL2 inhibitor and antiviral) verse standard care treatment on decrease ADRS, hyper inflammation, hypercytokinemia, and the mortality rate

NCT ID: NCT04968574 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Start date: August 26, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase 2, randomized, placebo controlled, multi-center study in subjects with mild to moderate IPF. Eligible subjects will be randomized to receive placebo or ENV-101 as a daily oral dose for 12 consecutive weeks of treatment. Following treatment, subjects will be observed for an additional 6 weeks.

NCT ID: NCT04931147 Completed - Inflammation Clinical Trials

A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers

Start date: May 13, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of RXC007.